Quince Therapeutics Inc., a biotechnology company focused on treating rare diseases, has announced the successful closing of a private placement of securities, raising approximately $11.5 million in upfront proceeds. The financing, which was priced at a premium, was led by Nantahala Capital, a healthcare-focused institutional investor, with participation from existing Quince shareholders such as ADAR1 Capital Management and members of Quince's senior management. The private placement includes common stock and accompanying warrants, with potential additional proceeds of up to $10.4 million if the warrants are exercised in full for cash. The funds will be used for working capital, general corporate purposes, and to advance the company's pivotal Phase 3 NEAT clinical trial in Ataxia-Telangiectasia (A-T), as well as to explore new program expansions into Duchenne muscular dystrophy and other rare diseases. This financing extends Quince's cash runway into at least the second quarter of 2026, supporting its ongoing research and development efforts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.